Biotech Boulevard
Startups and Spinouts
GEN's Biotech Boulevard highlights new entrepreneurial biotech firms based all over the globe. These unique companies are developing breakthrough products that will expand and enhance the biotech industry.
Discover, invest, and collaborate with these industry leaders of tomorrow.
Explore Biotech Boulevard. It's paved with opportunities!
GEN's Biotech Boulevard
All  All  A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z   0  1  2  3  4  5  6  7  8  9   
  • Dynamic Biosensors

    Dynamic Biosensors develops and commercializes the proprietary switchSENSE technology for molecular interaction analysis. In addition to binding affinity and kinetics, the dynamic character switchSENSE allows to determine molecular size, conformational changes, charge, and certain post-translational modifications of the target in the same measurement. Dynamic Biosensors is a spin-off of the Technische Universität München.

  • eADMET

    eADMET is an expert in the creation of customized computational models for the prediction of important ADME/Tox properties of small drug-like molecules. The company’s modular approach combines proprietary and selected external algorithms to inform the creation of customized prediction models (with integrated error estimation) for clients and partners from the pharmaceutical and biotechnology industry.

  • Elcelyx Therapeutics

    Elcelyx Therapeutics is a privately-held company developing products for weight management and obesity-related metabolic disorders based on the science of nutrient sensing. Elcelyx product candidates, Lovidia™ and NewMet™, are Gut Sensory Modulators backed by research and clinical data demonstrating their ability to rapidly reduce weight and improve glucose metabolism without systemic side effects, respectively.

  • Ember Therapeutics

    Ember Therapeutics is a product-focused company translating its biology in the emerging area of brown fat and recent breakthroughs in understanding the mechanisms of selective insulin sensitivity into a proprietary pipeline of peripherally-acting treatments for metabolic disease, including Type 2 diabetes and obesity. 

  • Envoy Therapeutics

    Envoy’s mission is to change drug discovery by advancing new drugs that act on targets expressed specifically in the cell populations important to diseases.  Their goal is to bring forth drugs that help millions of people while causing fewer side effects.  Envoy hopes to achieve this mission through their powerful technology, called “bacTRAP”, that allows them to measure, in vivo, the expression of each protein within any given cell type.

  • Eqalix

    Eqalix is an emerging regenerative medicine development company with a goal of enhancing the quality of life of consumers and patients by providing nano-materials for the repair and regeneration of diseased, traumatized, and aging tissues. The company plans to develop and commercialize a plant-protein based nano-fiber scaffold for use in consumer markets and as a human skin substitute; small-diameter hybrid vessels that foster the creation of a functional endothelium after implantations; and 3D tissue scaffolds with adjustable properties for organ and tissue replacement and repair.

  • Eudendron

    Eudendron is a start-up company devoted to the discovery and development of a new generation of Kinase inhibitors in the area of oncology personalized medicine. The company's molecular design aims to develop safer and effective drugs able to overcome drug resistance. Eudendron’s new generation of Kinase inhibitors will be the result of a drug process called KemKinase, which encloses molecular designs and in silico validation technology coupled to a Kinome-wide strategy, revealing at a very early stage the full spectrum of Kinase targets associated to the newly identified chemical classes.

  • Flexion Therapeutics

    Flexion Therapeutics discovers and develops innovative therapeutics for musculoskeletal disorders. In order to provide safe and effective products, they are merging novel pharmacology with local, sustained delivery of drug to the site of disease; an approach that aims to ensure lasting therapeutic effect and systemic safety.

  • Foundation Medicine

    Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company’s initial clinical product, FoundationOne™, is a fully informative genomic profile to identify a patient’s individual molecular alterations and match them with relevant targeted therapies and clinical trials.


  • Gamma Therapeutics

    Gamma Therapeutics is an early stage biotechnology venture developing solutions for cardiovascular disease risk assessment, biosurgical therapy and combat casualty care based upon the use of human biocompatible proteins, such as Gamma Prime Fibrinogen, responsible for the clotting mechanism in human blood. The product line includes its patent-pending flagship product, GammaCoeur™, a cardiovascular disease risk assessment assay; GammaSeal™, a patented, high strength surgical incision and wound healing sealant; Gammarin™, a patented anticoagulant blood thinner for use during and after surgery, and; GammaTF, a provisionally-patented fast-clotting hemostatic dressing for hemorrhage control.


© 2012 Genetic Engineering & Biotechnology News. All Rights Reserved.
Back to